Rhodiola vs Ashwagandha: Which Adaptogen Wins for Stress, Energy, and Focus?

The 30-Second Answer

Rhodiola rosea and ashwagandha (Withania somnifera) are the two adaptogenic roots most often cross-shopped for stress, energy, and focus. They are not interchangeable.

• Rhodiola is the stronger pick for acute mental fatigue, burnout-pattern symptoms, and fast onset. Effects emerge within days at 200–576 mg/day of branded extracts (SHR-5, WS 1375).
• Ashwagandha is the stronger pick for chronic perceived stress, morning serum cortisol, and sleep continuity. Effects build over 8–12 weeks at 240–600 mg/day standardized root extract.
• Extraction method matters more than most labels admit. Supercritical CO2 (SFE) operates above 31 °C and 74 bar, leaves zero ethanol or hexane residue, and preserves heat-labile compounds (salidroside, rosavin, withanolides) in a way ethanolic and hexane-pulled commodity extracts struggle to match.
• Pick by your stress pattern. Acute, situational, brain-fog stress points to rhodiola. Chronic, sleep-disrupting stress points to ashwagandha.

We don't sell rhodiola. CafeBank's three SKUs use tongkat ali, guarana, and maca — all SFE-extracted — so if your read of the evidence routes you to a rhodiola-shaped need, we'll point you to a separate vendor and tell you what to look for on the label. We will also tell you when our SKU stack is the better-evidenced match for the energy-plus-stress bucket.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

What Rhodiola rosea Actually Is

The Arctic adaptogen

Rhodiola rosea is a perennial succulent from cold high-altitude regions of the Northern Hemisphere — Scandinavia, the Russian Arctic, the Altai mountains. Soviet-era physiology research catalogued it as part of the "adaptogen" class. Modern Western research clusters at the Swedish Herbal Institute (SHR-5) and the German Dr. Willmar Schwabe pharma group (WS 1375 / Rhodax).

Salidroside and rosavin — the actives that matter

The two compound families most associated with clinical effects are salidroside (a phenylpropanoid glycoside) and the rosavins. Traditional standardization is roughly 3 % rosavins and 1 % salidroside — the ratio Olsson 2009 SHR-5 trials used. "Rhodiola extract" without a stated standardization is not what the literature studied.

Extract-quality variation: SHR-5, WS 1375, Rhodax, Rhodiolife

SHR-5 anchors Olsson 2009 (PMID 19016404), Spasov 2000 (PMID 10839209), Darbinyan 2000 (PMID 11081987). WS 1375 anchors Kasper & Dienel 2017 (PMID 28367055), Edwards 2012 (PMID 22228617), Lekomtseva 2017 (PMID 28219059). Rhodax was used in Bystritsky 2008 (PMID 18307390).

Why "rhodiola" does not always mean Rhodiola rosea

There are roughly 200 Rhodiola species. Rhodiola crenulata dominates parts of the Asian commodity market and is chemically distinct. If a label says only "rhodiola" and not "Rhodiola rosea," assume it is not what the trials studied.

What Ashwagandha Is (Brief)

The full read is in our ashwagandha-vs-maca breakdown. Short version: ashwagandha is Withania somnifera, an Ayurvedic shrub root with a clinical-trial base concentrated on perceived stress reduction, morning serum cortisol reduction, and sleep continuity in stressed-but-healthy adults. Dose range that moves endpoints: 240–600 mg/day standardized root extract over 8–12 weeks (Chandrasekhar 2012, PMID 23439798; Lopresti 2019, PMID 31517876; Salve 2019, PMID 32021735; Langade 2020, PMID 32818573).

KSM-66 vs Sensoril vs generic

KSM-66 (Ixoreal) and Sensoril (Natreon) anchor most of the modern ashwagandha trial base. KSM-66 is a full-spectrum root-only extract; Sensoril is a higher-withanolide root-and-leaf extract. Generic "ashwagandha 500 mg" without a stated extract is not what the trials studied — same caveat as SHR-5 / WS 1375 for rhodiola.

Head-to-Head Comparison Table

The infographic above renders this comparison visually. Accessible text version follows.

Dimension	Rhodiola rosea	Ashwagandha	Better-evidenced
Onset speed	Day 3 (Edwards 2012); week 1 (Kasper 2017)	60–90 days	Rhodiola
Stress (acute)	Spasov 2000; Darbinyan 2000; Olsson 2009	Not the lane	Rhodiola
Stress (chronic)	Anghelescu 2018; HMPC/EMA-approved indication	3 placebo-controlled RCTs at 240–600 mg/day	Ashwagandha
Mental fatigue	Fatigue Index in night-duty physicians (Darbinyan 2000); MFI-20 (Lekomtseva 2017)	Secondary in stress RCTs	Rhodiola
Physical performance	Wang 2025 meta — VO2max, TTE, TTP at >600 mg/day	Strength and recovery signal	Mixed — rhodiola endurance, ashwagandha strength
Mood / depression	Darbinyan 2007; Urata 2025; not equivalent to sertraline (Mao 2015)	Secondary endpoints in stress RCTs	Rhodiola for mild-to-moderate; neither replaces clinical antidepressants
Anxiety	Cropley 2015 (untreated controls); n=10 GAD pilot (Bystritsky 2008) hypothesis-generating only	HARS reductions (Lopresti 2019)	Ashwagandha
Sleep	Not a primary endpoint; can over-activate if dosed late	SOL and efficiency (Langade 2020); meta SMD -0.59 (Cheah 2021)	Ashwagandha
Cortisol	Cortisol awakening response (Olsson 2009)	Morning serum cortisol across 3 RCTs	Ashwagandha
Typical dose	200–576 mg/day SHR-5 or WS 1375	240–600 mg/day standardized root	Comparable mg, different extract identity
Cycling	Traditional 4–6 weeks on, 1–2 weeks off	Continuous up to 90 days	Neither has long-tail data
Cost / day (US, 2026)	$0.40–1.20 for branded SHR-5 or WS 1375	$0.30–0.90 for KSM-66 or Sensoril	Comparable
Who should consider	Acute, situational stress; mental-fatigue dominant; need fast onset	Chronic background stress; sleep-disruption dominant	Different stress profiles → different herbs

Where Rhodiola Has the Stronger Evidence

Acute mental fatigue under stress

Darbinyan 2000 (PMID 11081987) — double-blind crossover RCT, 56 physicians on night duty, 170 mg/day SHR-5 × 14 days; significant Fatigue Index improvement versus placebo. Spasov 2000 (PMID 10839209) — parallel RCT, 60 students through an exam period on low-dose SHR-5; significant improvements in physical fitness, mental fatigue, and neuro-motoric tests at p < 0.01.

Burnout-pattern symptoms

Kasper & Dienel 2017 (PMID 28367055) — 118 outpatients with burnout symptoms, 400 mg/day WS 1375 × 12 weeks, open-label multicenter single-arm. Most measures improved by week 1 and continued through week 12. No placebo group — framing is "directional evidence with the strongest available signal," not "proven remedy for burnout."

Olsson 2009 (PMID 19016404) — the controlled counterpart: 60 adults with stress-related fatigue, 576 mg/day SHR-5 × 28 days, double-blind placebo-controlled. Significant improvement on the Pines burnout scale and CCPT II attention indices, plus reduction in cortisol awakening response (not general cortisol — see Honest Take).

Edwards 2012 (PMID 22228617) — 101 adults with life-stress symptoms, 200 mg twice daily WS 1375 × 4 weeks, improvements detectable by day 3. Open-label.

Mild anxiety in non-clinical populations

Cropley 2015 (PMID 26502953) — 80 mildly anxious adults, 2 × 200 mg/day Vitano × 14 days vs untreated controls; significant reductions in self-reported anxiety, stress, anger, confusion, depression; no cognitive-performance difference. Untreated controls, not placebo. Bystritsky 2008 (PMID 18307390) — open-label pilot in 10 GAD patients, 340 mg/day Rhodax × 10 weeks; HARS dropped. n = 10, no control — hypothesis-generating only.

Endurance performance at higher doses

Wang 2025 (PMID 41080184) — meta-analysis of 26 RCTs, 668 subjects, with significant improvements on VO2max (ES 0.32), TTE (0.38), TTP (-0.40). CK and MDA markers improved. Greater effects above 600 mg/day. Lu 2022 (PMID 35464040) — 10 studies, reduced muscle pain, enhanced antioxidant capacity, explosive-power gains. Sanz-Barrio 2023 (PMID 37495266) is the cautious read — see Limitations.

Mechanism

Ivanova Stojcheva 2022 (PMID 35745023) synthesizes mechanism across 20+ clinical trials: HPA-axis modulation, with downstream effects on serotonin, catecholamine, and β-endorphin pathways. Anghelescu 2018 (PMID 29325481) notes rhodiola rosea extract is the main adaptogen approved by the European Medicines Agency's HMPC for the "stress" indication. Adaptogen-class behavior, not stimulant, not sedative.

Where Ashwagandha Has the Stronger Evidence

For the full read, see our ashwagandha-vs-maca breakdown. The short list:

• Chronic perceived stress and morning cortisol. Three independent placebo-controlled RCTs at 240–600 mg/day over 60–90 days reduced PSS scores and morning serum cortisol versus placebo (Chandrasekhar 2012, PMID 23439798; Lopresti 2019, PMID 31517876; Salve 2019, PMID 32021735). Rhodiola has no equivalent placebo-controlled morning-cortisol stack.
• Sleep onset and efficiency. Langade 2020 (PMID 32818573) showed significant improvements in both, with stronger effects in the insomnia subgroup. Cheah 2021 (PMID 34559859) pooled five sleep RCTs into a meta with SMD -0.59.
• Strength and recovery. Ashwagandha's strength-training base is more robust than rhodiola's at this endpoint.
• Continuous (non-cyclical) use. Ashwagandha trials run 8–12 weeks of continuous dosing without the on-off pattern more common in rhodiola.

The Honest Take on Rhodiola for Depression

High-scrutiny YMYL section. Read slowly.

Three trials anchor the conversation:

• Darbinyan 2007 (PMID 17990195) — placebo-controlled RCT in 89 patients with mild-to-moderate depression on 340 or 680 mg/day SHR-5 for 6 weeks. Active arms produced significant improvements versus placebo on HAM-D, BDI, and on insomnia, emotional instability, and somatization subscales.
• Mao 2015 (PMID 25837277) — head-to-head versus sertraline in 57 adults with major depressive disorder. Sertraline reduced HAM-D more than rhodiola, but neither arm was statistically significantly different from placebo in this underpowered trial. Adverse-event rates favored rhodiola (30 % vs 63.2 % sertraline).
• Gao 2020 (PMID 32090788) — rhodiola as augmentation to sertraline rather than replacement. 100 adults with MDD; combination outperformed sertraline alone on HAM-D, BDI, and CGI. 0.6 g/day better than 0.3 g/day. Augmentation under physician supervision, not self-medication.

Urata 2025 (PMID 40014460) meta-analyzed 8 RCTs (1,049 subjects) of pharmacological interventions for milder depression and found rhodiola produced significant improvements versus placebo in pooled analysis — while explicitly flagging "paucity of high-quality RCTs."

The institutional counterweight matters. The MSD Manual notes that the World Federation of Societies of Biological Psychiatry (WFSBP) and the Canadian Network for Mood and Anxiety Treatments (CANMAT) do not currently support rhodiola monotherapy for major depressive disorder.

Reader-facing framing: rhodiola may help mild-to-moderate depressive symptoms in some studies, with the clearest benefit as augmentation alongside a clinician-prescribed antidepressant — never as a substitute. If you have a major depressive episode, the right call is a physician.

How Extraction Method Changes Everything

Ethanol — solvent residue and salidroside degradation

Ethanol is the default solvent for most commodity rhodiola extracts. Cheap and reasonably efficient at pulling rosavins, but leaves measurable residue, and the heat used to drive it off can degrade salidroside. Commercial-quality assessments document salidroside-to-rosavin ratio variability across ethanol-extracted products that does not match the standardization SHR-5 and WS 1375 trials studied.

Hexane — cheap and problematic

Hexane is a petrochemical solvent used in some commodity extracts. Cost-efficient at scale but carries residue concerns and is less suitable for heat-sensitive phenylpropanoid glycosides. Trial-grade extracts do not use hexane.

Supercritical CO2 (SFE) — why it's different

SFE operates above CO2's critical point (roughly 31 °C and 74 bar). CO2 dissolves target compounds with high selectivity, then evaporates cleanly when pressure drops: zero solvent residue, no ethanol or hexane carryover, lower thermal stress on heat-sensitive actives. CafeBank uses SFE for the tongkat ali, guarana, and maca in our blends. We do not produce a rhodiola SKU — but if you are buying rhodiola separately, an SFE-extracted standardized SHR-5 or WS 1375 product is a stronger structural match to trial-grade material than an ethanol generic.

Rosavin-to-salidroside ratio

Trial-grade rhodiola is typically standardized to roughly 3 % rosavins and 1 % salidroside — the ratio SHR-5 and WS 1375 trial materials hit. Labels stating only total milligrams without a standardization spec do not tell you what is in the capsule.

How to Read a Rhodiola Label

• Species explicitly stated — look for "Rhodiola rosea," not just "rhodiola."
• Standardization spec present — "3 % rosavins / 1 % salidroside" or close.
• Branded extract preferred — SHR-5 and WS 1375 have the deepest human-trial base.
• Extraction method disclosed — SFE is cleanest; standardized ethanol acceptable; avoid hexane.
• Third-party testing — reputable brands publish certificates of analysis.

How to Stack Rhodiola (or Not) With Coffee

We are a coffee company, so we have to be especially honest here.

Rhodiola plus caffeine — timing matters

Rhodiola is adaptogenic rather than stimulant in the trial literature. Some users report a subtle activating effect when rhodiola is combined with caffeine, particularly in the late afternoon or evening — consistent with the mechanism picture in Ivanova Stojcheva 2022 (HPA-axis modulation plus serotonin and catecholamine pathway activity). Morning dosing alongside a first coffee is well tolerated for most readers. Sensitive responders can experience restlessness, jitter, or sleep-onset disruption if dosed too late.

When it over-activates

If you are anxiety-prone, prone to insomnia, or already drinking heavily caffeinated coffee through the afternoon, layering rhodiola on top can tip from "alert and clear" into "wired and unable to settle." Most trials dosed rhodiola early in the day. The practical rule: morning only, avoid dosing within 6 hours of bedtime, watch for over-activation if you are caffeine-sensitive.

The CafeBank approach

We do not put rhodiola in any of our SKUs. Our 20g flagship (Exclusive Blend VIP Coffee) pairs tongkat ali, guarana, and maca for an energy-plus-male-focus positioning; our 10g daily-driver (Active Blend VIP Coffee) drops tongkat and runs maca + guarana for a lighter daily-energy + mood profile; the VIP Coffee Tablets carry the same maca + guarana pair in a portable format. Our guarana vs coffee complete guide covers the caffeine-herb synergy in depth.

Dosing, Timing, Cycling

Standard dose: 200–600 mg/day standardized extract

The trial-supported range is 200–600 mg/day of a standardized SHR-5 or WS 1375 extract. Spasov 2000 used under 200 mg/day. Olsson 2009 used 576 mg/day. Kasper 2017 used 400 mg/day. Wang 2025's endurance meta showed greater benefit above 600 mg/day. Doses above 600 mg/day have not been characterized for chronic safety.

Extract-specific ranges

• SHR-5: 144 mg/day (Darbinyan 2000) up to 576 mg/day (Olsson 2009).
• WS 1375: 200–400 mg/day in burnout, life-stress, and chronic-fatigue trials.
• Rhodax: 340 mg/day in the Bystritsky 2008 GAD pilot.
• Rhodiolife: smaller trial base — confirm standardization spec before using.

Cycle: 4–6 weeks on, 1–2 weeks off

The traditional rhodiola cycling pattern is 4–6 weeks on followed by 1–2 weeks off. Most published trials run 4–12 weeks of continuous dosing. The cycling convention comes from Russian adaptogen practice and is repeated widely by rhodiola brands, but its evidence basis is traditional rather than RCT-derived. Ashwagandha, by contrast, is more commonly dosed continuously over 8–12 weeks. Daily forever rhodiola use sits outside the studied window.

Morning vs pre-workout timing

Mental-fatigue and stress endpoints used morning dosing or a split AM/early-afternoon schedule. Endurance trials in the Wang 2025 meta were typically dosed pre-workout. Avoid evening dosing — see the Coffee section.

Limitations and Null Results

Mao 2015 — null between active arms and placebo. In the head-to-head versus sertraline (PMID 25837277), neither rhodiola nor sertraline reached statistical significance versus placebo on HAM-D in n = 57. Sertraline numerically beat rhodiola, but in an underpowered trial both arms missed the placebo-comparison bar. Anyone citing rhodiola as "as effective as sertraline" is over-reading this paper.

Sanz-Barrio 2023 — chronic supplementation does not improve endurance. Systematic review of 13 RCTs (263 subjects, PMID 37495266): acute rhodiola improved endurance and RPE, but chronic supplementation did not. Chronic did improve anaerobic performance and reduce muscle-damage markers. Heterogeneity high, bias risk substantial — rhodiola is more interesting as an acute pre-workout intervention than a chronic daily endurance enhancer.

Open-label and high-bias designs. Kasper 2017, Edwards 2012, Lekomtseva 2017, and Bystritsky 2008 are open-label, single-arm, or uncontrolled. Cropley 2015 used untreated rather than placebo controls. Older systematic reviews (Ishaque 2012 in the broader literature) flagged a high overall risk of bias across the rhodiola trial base.

Trial duration cap. Most RCTs run 4–12 weeks. Long-term safety beyond 12 weeks is not well-characterized in placebo-controlled data.

Branded-extract specificity. Almost all positive findings come from a small set of branded extracts. The evidence does not cleanly extrapolate to generic "rhodiola extract" capsules.

Safety, Side Effects, and Who Should Avoid

YMYL safety section.

Common adverse events

Most commonly reported: dizziness and dry mouth (Bystritsky 2008, PMID 18307390); some users report insomnia or over-activation if dosed late. Trial-level rates are low — Kasper 2017 reported 0.015 events per observation day; Mao 2015 reported 30 % on rhodiola vs 63.2 % on sertraline.

CYP2C9 inhibition — warfarin, phenytoin, losartan

Thu 2016 (PMID 26613955) measured CYP-enzyme activity in 13 healthy volunteers given commercial rhodiola for 14 days, documenting a 21 % reduction in the EXP-3174-to-losartan ratio — a statistically significant inhibition of CYP2C9. Warfarin, phenytoin, and losartan have narrow therapeutic indices, so a 21 % shift in clearance can move blood levels meaningfully. Anyone on warfarin, phenytoin, or losartan should not start rhodiola without a physician's review. MSKCC's Herbs Database also documents preclinical CYP3A4 inhibition signals.

Tachyarrhythmia case report — combined with antidepressants

MSKCC documents a 26-year-old woman hospitalized with tachyarrhythmia after three days of combining rhodiola with an antidepressant. Rare event, real published case. The mechanism plausibility is rhodiola's reported MAO-inhibition activity stacking with serotonergic medication. If you are on a serotonergic antidepressant, do not start rhodiola without clearing it with your prescribing physician.

Drug-class interactions

• Antidepressants (SSRIs, SNRIs, MAOIs, tricyclics). Reported MAO-inhibition activity; combination requires physician review. MSKCC tachyarrhythmia case is the named risk.
• Antihypertensives. May modestly lower blood pressure; additive effects documented in WebMD and MSKCC.
• Antidiabetics (insulin, sulfonylureas, metformin). May lower blood glucose; additive effects can risk hypoglycemia.
• Immunosuppressants (post-transplant, autoimmune therapies). May stimulate immune function; caution in MS, lupus, RA, post-transplant.
• CNS depressants and sedatives. Mild activating profile and MAO-inhibition can reduce sedative efficacy or cause unpredictable CNS effects.

Pregnancy and breastfeeding

Insufficient safety data. MSKCC, WebMD, and MSD Manual all advise against rhodiola during pregnancy and breastfeeding. Hard stop.

Bipolar disorder

Mild stimulant and mood-elevating properties. Anecdotal reports of mania induction in bipolar patients in the integrative-medicine literature. Bipolar disorder is a contraindication. Same caution for anyone with a history of manic or hypomanic episodes.

Autoimmune disease

Reported immune-stimulating activity makes it a caution in autoimmune conditions — MS, lupus, RA, post-transplant — consistent with precaution patterns for ginseng and other immunomodulatory adaptogens.

Duration cap

Most RCTs run 4–12 weeks. Long-term continuous use beyond 12 weeks is not well-studied.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Our Verdict: When to Pick Rhodiola, When to Pick Ashwagandha

• Pick rhodiola if your stress is acute and situational — exam pressure, a hard work sprint, shift-work fatigue, brain-fog under deadline. Pick rhodiola if you want fast onset (days, not weeks) and evening sleep is not your dominant complaint. Pick rhodiola if you train and care about endurance pre-workout.
• Pick ashwagandha if your stress is chronic and background — months of accumulated load, sleep disruption, morning cortisol spike. Our ashwagandha-vs-maca breakdown is the deeper read.
• Need both? Consider alternating — six weeks of rhodiola during a sprint, then ashwagandha during a recovery and sleep-rebuild phase — not stacking simultaneously. Combination has not been studied in published RCTs.
• Looking at this from an energy-plus-stress lens? Our SKUs are built for that bucket using SFE-extracted tongkat ali, guarana, and maca. The 20g Exclusive Blend VIP Coffee adds tongkat to the maca + guarana pair (read the complete tongkat ali guide; cross-comparison with ginseng in our ginseng vs tongkat ali breakdown). The 10g Active Blend VIP Coffee drops tongkat for a lighter daily driver alongside maca's energy-root profile. The VIP Coffee Tablets carry the same maca + guarana pair in a portable format.

What CafeBank does not do: sell rhodiola. If your read of the evidence is that rhodiola is the right match, source it from another vendor — pick a brand that names the species, states the standardization (3 % rosavins / 1 % salidroside), uses a branded extract (SHR-5 or WS 1375 preferred), and ideally uses supercritical CO2 extraction.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Frequently Asked Questions

Can I take rhodiola and ashwagandha together? No published RCT has tested the combination. Mechanisms are distinct — rhodiola is acute-onset HPA-axis-modulating with serotonergic activity; ashwagandha is slower-onset chronic-cortisol-reducing. A "morning rhodiola, evening ashwagandha" pattern is used in practice but sits outside the controlled evidence base. A safer alternative is alternating cycles: six weeks of one, then switch.

How long until rhodiola starts working? Faster than ashwagandha. Edwards 2012 — symptom improvements from day 3. Kasper 2017 — most measures by week 1. Olsson 2009 — clear endpoint movement at 4 weeks. If you have not noticed any effect after 3–4 weeks of a standardized SHR-5 or WS 1375 extract at 200–400 mg/day, the signal probably is not for you.

Is rhodiola safe to take with coffee? For most people taking it together in the morning, yes. For caffeine-sensitive responders, those prone to anxiety or insomnia, or anyone dosing in late afternoon or evening, the combination can produce restlessness, jitter, or sleep-onset disruption. Trials dosed rhodiola early in the day for a reason. See our guarana vs coffee complete guide for the broader caffeine-herb stacking framework.

Rhodiola vs ginseng — which is better for energy? Different profiles. Rhodiola wins on acute mental-fatigue and stress-triggered focus loss with fast onset. Ginseng has a deeper traditional-use base and is more commonly compared with tongkat ali for male energy. Our ginseng vs tongkat ali breakdown is the closest comparison pillar.

Does rhodiola raise or lower cortisol? Olsson 2009 (PMID 19016404) showed reduced cortisol awakening response in patients with stress-related fatigue — narrower than "lowers cortisol generally." Ashwagandha has a more robust morning-serum-cortisol signal across three placebo-controlled RCTs.

Is rhodiola safe for women? Trial base includes both sexes with no sex-specific safety signals. Pregnancy and breastfeeding are contraindicated regardless. Anyone on hormonal contraception or hormone-modulating therapy should mention rhodiola to their physician given the CYP2C9 interaction profile.

Can I take rhodiola long-term? Most published trials run 4–12 weeks. Traditional cycling: 4–6 weeks on, 1–2 weeks off. Long-term continuous use beyond 12 weeks is not well-characterized. Re-evaluate at three months.

Does rhodiola interact with SSRIs? Yes, with caution. The MSKCC tachyarrhythmia case in a 26-year-old woman combining rhodiola with an antidepressant is the named published risk, plausibly mediated by rhodiola's MAO-inhibition activity stacking with serotonergic medication. Anyone on an SSRI, SNRI, MAOI, or tricyclic should not start rhodiola without clearance from their prescribing physician.

What are rhodiola's common side effects? Dizziness and dry mouth (Bystritsky 2008); occasional insomnia or over-activation if dosed late. Trial-level rates are low — Kasper 2017 reported 0.015 events per observation day. Mao 2015 reported 30 % adverse events on rhodiola versus 63.2 % on sertraline.

How much rhodiola should I take? 200–600 mg/day of a standardized SHR-5 or WS 1375 extract (3 % rosavins / 1 % salidroside). Lower-end studies used 144–200 mg/day; Olsson 2009 used 576 mg/day; endurance benefit in Wang 2025 greater above 600 mg/day. Doses beyond 600 mg/day not characterized for chronic safety. Start low, take in the morning, give it 3–4 weeks.

Is it safe to take rhodiola with blood thinners? Use caution with physician oversight. Thu 2016 (PMID 26613955) documented 21 % CYP2C9 inhibition — clinically relevant for warfarin, phenytoin, and losartan with narrow therapeutic indices. Anyone on warfarin should not start rhodiola without their physician adjusting INR monitoring. MSD Manual names the warfarin interaction as documented.

Who should avoid rhodiola entirely? - Pregnant or breastfeeding women. - People with bipolar disorder or a history of manic or hypomanic episodes. - People with autoimmune conditions or on immunosuppressants. - People on warfarin, phenytoin, or losartan without physician oversight. - People on SSRIs, SNRIs, MAOIs, or tricyclics without prescribing-physician clearance. - People with active thyroid disease without physician oversight. - Children — pediatric safety has not been established.

Disclaimer

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Information in this article is educational and reflects the published literature as of April 2026. It is not a substitute for individualized medical advice. Consult a qualified healthcare practitioner before starting any supplement, especially if pregnant, breastfeeding, with a diagnosed medical condition, or on prescription medication.

References

1. Kasper S, Dienel A. (2017). Multicenter, open-label, exploratory clinical trial with Rhodiola rosea extract in patients suffering from burnout symptoms. Neuropsychiatr Dis Treat. 13:889-898. DOI: 10.2147/NDT.S120113. PMID: 28367055.
2. Olsson EMG, von Schéele B, Panossian AG. (2009). A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Med. 75(2):105-12. DOI: 10.1055/s-0028-1088346. PMID: 19016404.
3. Edwards D, Heufelder A, Zimmermann A. (2012). Therapeutic effects and safety of Rhodiola rosea extract WS® 1375 in subjects with life-stress symptoms — results of an open-label study. Phytother Res. 26(8):1220-5. DOI: 10.1002/ptr.3712. PMID: 22228617.
4. Anghelescu IG, Edwards D, Seifritz E, Kasper S. (2018). Stress management and the role of Rhodiola rosea: a review. Int J Psychiatry Clin Pract. 22(4):242-252. DOI: 10.1080/13651501.2017.1417442. PMID: 29325481.
5. Cropley M, Banks AP, Boyle J. (2015). The Effects of Rhodiola rosea L. Extract on Anxiety, Stress, Cognition and Other Mood Symptoms. Phytother Res. 29(12):1934-9. DOI: 10.1002/ptr.5486. PMID: 26502953.
6. Spasov AA, Wikman GK, Mandrikov VB, Mironova IA, Neumoin VV. (2000). A double-blind, placebo-controlled pilot study of the stimulating and adaptogenic effect of Rhodiola rosea SHR-5 extract on the fatigue of students caused by stress during an examination period with a repeated low-dose regimen. Phytomedicine. 7(2):85-9. DOI: 10.1016/S0944-7113(00)80078-1. PMID: 10839209.
7. Darbinyan V, Kteyan A, Panossian A, Gabrielian E, Wikman G, Wagner H. (2000). Rhodiola rosea in stress induced fatigue — a double blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty. Phytomedicine. 7(5):365-71. DOI: 10.1016/S0944-7113(00)80055-0. PMID: 11081987.
8. Lekomtseva Y, Zhukova I, Wacker A. (2017). Rhodiola rosea in Subjects with Prolonged or Chronic Fatigue Symptoms: Results of an Open-Label Clinical Trial. Complement Med Res. 24(1):46-52. DOI: 10.1159/000457918. PMID: 28219059.
9. Darbinyan V, Aslanyan G, Amroyan E, Gabrielyan E, Malmström C, Panossian A. (2007). Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry. 61(5):343-8. DOI: 10.1080/08039480701643290. PMID: 17990195.
10. Mao JJ, Xie SX, Zee J, Soeller I, Li QS, Rockwell K, Amsterdam JD. (2015). Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial. Phytomedicine. 22(3):394-9. DOI: 10.1016/j.phymed.2015.01.010. PMID: 25837277.
11. Gao L, Wu C, Liao Y, Wang J. (2020). Antidepressants effects of Rhodiola capsule combined with sertraline for major depressive disorder: A randomized double-blind placebo-controlled clinical trial. J Affect Disord. 265:99-103. DOI: 10.1016/j.jad.2020.01.065. PMID: 32090788.
12. Bystritsky A, Kerwin L, Feusner JD. (2008). A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). J Altern Complement Med. 14(2):175-80. DOI: 10.1089/acm.2007.7117. PMID: 18307390.
13. Wang X, Yang X, Gao Z, Zeng J, Liu Y. (2025). The effect of Rhodiola rosea supplementation on endurance performance and related biomarkers: a systematic review and meta-analysis. Front Nutr. 12:1645346. DOI: 10.3389/fnut.2025.1645346. PMID: 41080184.
14. Sanz-Barrio PM, Noreen EE, Gilsanz-Estebaranz L, Lorenzo-Calvo J, Martínez-Ferrán M, Pareja-Galeano H. (2023). Rhodiola rosea supplementation on sports performance: A systematic review of randomized controlled trials. Phytother Res. 37(10):4414-4428. DOI: 10.1002/ptr.7950. PMID: 37495266.
15. Lu Y, Deng B, Xu L, Liu H, Song Y, Lin F. (2022). Effects of Rhodiola Rosea Supplementation on Exercise and Sport: A Systematic Review. Front Nutr. 9:856287. DOI: 10.3389/fnut.2022.856287. PMID: 35464040.
16. Ivanova Stojcheva E, Quintela JC. (2022). The Effectiveness of Rhodiola rosea L. Preparations in Alleviating Various Aspects of Life-Stress Symptoms and Stress-Induced Conditions — Encouraging Clinical Evidence. Molecules. 27(12):3902. DOI: 10.3390/molecules27123902. PMID: 35745023.
17. Thu OK, Spigset O, Nilsen OG, Hellum B. (2016). Effect of commercial Rhodiola rosea on CYP enzyme activity in humans. Eur J Clin Pharmacol. 72(3):295-300. DOI: 10.1007/s00228-015-1988-7. PMID: 26613955.
18. Urata M, et al. (2025). Efficacy of Pharmacological Interventions in Milder Depression: A Systematic Review and Meta-Analysis. Neuropsychopharmacol Rep. 45(1):e70008. DOI: 10.1002/npr2.70008. PMID: 40014460.
19. Chandrasekhar K, Kapoor J, Anishetty S. (2012). A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med. 34(3):255-62. DOI: 10.4103/0253-7176.106022. PMID: 23439798.
20. Lopresti AL, Smith SJ, Malvi H, Kodgule R. (2019). An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: A randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 98(37):e17186. DOI: 10.1097/MD.0000000000017186. PMID: 31517876.
21. Salve J, Pate S, Debnath K, Langade D. (2019). Adaptogenic and Anxiolytic Effects of Ashwagandha Root Extract in Healthy Adults: A Double-blind, Randomized, Placebo-controlled Clinical Study. Cureus. 11(12):e6466. DOI: 10.7759/cureus.6466. PMID: 32021735.
22. Langade D, Thakare V, Kanchi S, Kelgane S. (2020). Clinical evaluation of the pharmacological impact of ashwagandha root extract on sleep in healthy volunteers and insomnia patients: A double-blind, randomized, parallel-group, placebo-controlled study. J Ethnopharmacol. 264:113276. DOI: 10.1016/j.jep.2020.113276. PMID: 32818573.
23. Cheah KL, Norhayati MN, Husniati Yaacob L, Abdul Rahman R. (2021). Effect of Ashwagandha (Withania somnifera) extract on sleep: A systematic review and meta-analysis. PLoS One. 16(9):e0257843. DOI: 10.1371/journal.pone.0257843. PMID: 34559859.
24. Gopukumar K, Thanawala S, Somepalli V, Rao TSS, Thamatam VB, Chauhan S. (2021). Efficacy and Safety of Ashwagandha Root Extract on Cognitive Functions in Healthy, Stressed Adults: A Randomized, Double-Blind, Placebo-Controlled Study. Evid Based Complement Alternat Med. 2021:8254344. DOI: 10.1155/2021/8254344. PMID: 34858513.

Institutional references

• Memorial Sloan Kettering Cancer Center, Integrative Medicine Herbs Database — Rhodiola. Permalink: https://www.mskcc.org/cancer-care/integrative-medicine/herbs/rhodiola (updated 2026-04-16). Source for CYP3A4 / CYP2C9 / P-gp inhibition and the 26-year-old tachyarrhythmia case report.
• MSD Manual, Professional Edition — Rhodiola. Permalink: https://www.msdmanuals.com/professional/special-subjects/dietary-supplements/rhodiola (updated 2025-07-03). Source for the WFSBP / CANMAT non-recommendation for rhodiola monotherapy in MDD and the warfarin-interaction note.
• WebMD — Rhodiola. Permalink: https://www.webmd.com/vitamins/ai/ingredientmono-883/rhodiola. Source for general dosing range and antihypertensive / antidiabetic / immunosuppressant interaction notes.

Citations retrieved from PubMed.